Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X instruments i...
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...
Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology Sales...
Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organ...
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition ...
Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the s...
“The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as part...
Modi Ventures, a newly launched venture partnership investing in fund managers and founders building companies shaping the future of humanity, today announ...
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make ...
Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A liv...
Lenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence in North America Boos...
“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silenc...
Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the fir...
Under CEO Alan Hirzel’s leadership, Abcam has transformed as a business, created significant value for all stakeholders, and outperformed the m...
© 2024 Biopharma Boardroom. All Rights Reserved.
